| Year |
Citation |
Score |
| 2021 |
Pikman Y, Tasian SK, Sulis ML, Stevenson K, Blonquist TM, Apsel Winger B, Cooper TM, Pauly M, Maloney KW, Burke MJ, Brown PA, Gossai N, McNeer JL, Shukla NN, Cole PD, ... ... Place AE, et al. Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory or High-risk Leukemias: A Report from the LEAP Consortium. Cancer Discovery. PMID 33563661 DOI: 10.1158/2159-8290.CD-20-0564 |
0.313 |
|
| 2020 |
Goldsmith KC, Verschuur A, Morgenstern DA, van Eijkelenburg N, Federico SM, Fraser C, Forlenza CJ, Ziegler DS, Gerber NU, Khaw SL, Cooper TM, Flotho C, Prine BA, Salem AH, Unnebrink K, ... ... Place AE, et al. The first report of pediatric patients with solid tumors treated with venetoclax. Journal of Clinical Oncology. 38: 10524-10524. DOI: 10.1200/Jco.2020.38.15_Suppl.10524 |
0.305 |
|
| 2019 |
Karol SE, Cooper TM, Bittencourt H, Gore L, O'Brien MM, Fraser C, Gambart M, Cario G, Zwaan CM, Bourquin J, Loh ML, Caron H, Prine B, Salem AH, Unnebrink K, ... ... Place AE, et al. Safety, Efficacy, and PK of the BCL2 Inhibitor Venetoclax in Combination with Chemotherapy in Pediatric and Young Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia: Phase 1 Study Blood. 134: 2649-2649. DOI: 10.1182/Blood-2019-129805 |
0.305 |
|
| 2019 |
Shulman DS, Vo KT, Fox E, Muscal JA, Walensky LD, Pikman Y, Stegmaier K, Church A, Crompton BD, Place AE, Chi SN, O'Neill AF, Kamihara J, Ezrre S, Carlowicz C, et al. Abstract CT112: A Phase I multicenter trial of the dual MDM2/MDMX inhibitor ALRN-6924 in children and young adults with relapsed/refractory pediatric cancers Cancer Research. 79. DOI: 10.1158/1538-7445.Am2019-Ct112 |
0.363 |
|
| 2018 |
Place AE, Pikman Y, Stevenson KE, Harris MH, Pauly M, Sulis ML, Hijiya N, Gore L, Cooper TM, Loh ML, Roti G, Neuberg DS, Hunt SK, Orloff-Parry S, Stegmaier K, et al. Phase I trial of the mTOR inhibitor everolimus in combination with multi-agent chemotherapy in relapsed childhood acute lymphoblastic leukemia. Pediatric Blood & Cancer. e27062. PMID 29603593 DOI: 10.1002/Pbc.27062 |
0.304 |
|
| 2018 |
Place AE, Goldsmith K, Bourquin JP, Loh ML, Gore L, Morgenstern DA, Sanzgiri Y, Hoffman D, Zhou Y, Ross JA, Prine B, Shebley M, McNamee M, Farazi T, Kim SY, et al. Accelerating drug development in pediatric cancer: a novel Phase I study design of venetoclax in relapsed/refractory malignancies. Future Oncology (London, England). PMID 29595064 DOI: 10.2217/Fon-2018-0121 |
0.377 |
|
| 2018 |
Gore L, Kearns PR, de Martino Lee ML, De Souza CA, Bertrand Y, Hijiya N, Stork LC, Chung NG, Cardos RC, Saikia T, Fagioli F, Seo JJ, Landman-Parker J, Lancaster D, Place AE, et al. Dasatinib in Pediatric Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Phase II Trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2017759597. PMID 29498925 DOI: 10.1200/Jco.2017.75.9597 |
0.321 |
|
| 2018 |
Sun W, Triche T, Malvar J, Gaynon P, Sposto R, Yang X, Bittencourt H, Place AE, Messinger Y, Fraser C, Dalla-Pozza L, Salhia B, Jones P, Wayne AS, Gore L, et al. A phase 1 study of azacitidine combined with chemotherapy in childhood leukemia: a report from TACL consortium. Blood. PMID 29339403 DOI: 10.1182/Blood-2017-09-803809 |
0.356 |
|
| 2018 |
Place AE, Blonquist TM, Stieglitz E, Cooper TM, Gore L, Aplenc R, Loh ML, Pauly M, Rau RE, Burke MJ, Etchin J, Look AT, Sulis ML, Silverman LB. Phase I Study of the Selinexor in Relapsed/Refractory Childhood Acute Leukemia Blood. 132: 1405-1405. DOI: 10.1182/Blood-2018-99-116689 |
0.315 |
|
| 2016 |
Townsend EC, Murakami MA, Christodoulou A, Christie AL, Köster J, DeSouza TA, Morgan EA, Kallgren SP, Liu H, Wu SC, Plana O, Montero J, Stevenson KE, Rao P, Vadhi R, ... ... Place AE, et al. The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell. 29: 574-86. PMID 27070704 DOI: 10.1016/J.Ccell.2016.03.008 |
0.321 |
|
| 2016 |
Silverman LB, Blonquist TM, Hunt SK, Kay-Green S, Athale UH, Clavell LA, Cole PD, Kelly KM, Laverdiere C, Leclerc J, Michon B, Schorin MA, Sulis ML, Welch JJG, Supko JG, ... ... Place AE, et al. Randomized Study of Pegasparagase (SS-PEG) and Calaspargase Pegol (SC-PEG) in Pediatric Patients with Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma: Results of DFCI ALL Consortium Protocol 11-001 Blood. 128: 175-175. DOI: 10.1182/Blood.V128.22.175.175 |
0.309 |
|
| 2016 |
Marusyk A, Tabassum D, Guerriero J, Place A, Rozhok A, Letai A, Polyak K. Abstract B24: Targeting hyaluronan sensitizes breast cancer-associated fibroblasts to lapatinib and overcomes stromal resistance Cancer Research. 76. DOI: 10.1158/1538-7445.Tme16-B24 |
0.319 |
|
| 2015 |
Place AE, Pikman Y, Stevenson K, Harris MH, Cooper TM, Gore L, Hijiya N, Loh ML, Pauly M, Sulis ML, Neuberg DS, Stegmaier K, Sallan SE, Silverman LB. Phase Ib Trial of the mTOR Inhibitor Everolimus Given in Combination with Multiagent Chemotherapy in Relapsed Acute Lymphoblastic Leukemia Blood. 126: 3765-3765. DOI: 10.1182/Blood.V126.23.3765.3765 |
0.317 |
|
| 2014 |
Sun W, Gaynon PS, Sposto R, Bittencourt H, Place AE, Messinger YH, Fraser C, Dalla-Pozza L, Giessen Jvd, Eckroth E, Yang X, Liang G, Jones PA, Wayne AS, Cooper T. A Phase 1 Study of Azacitidine (AZA) in Combination with Fludarabine and Cytarabine in Relapse/Refractory Childhood Leukemia: A Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study Blood. 124: 3764-3764. DOI: 10.1182/Blood.V124.21.3764.3764 |
0.345 |
|
| 2010 |
Honda T, Honda Y, Favaloro Jr. FG, Gribble GW, Suh N, Place AE, Rendi MH, Sporn MB. ChemInform Abstract: A Novel Dicyanotriterpenoid, 2-Cyano-3,12-dioxooleana-1,9(11)-dien-28-onitrile, Active at Picomolar Concentrations for Inhibition of Nitric Oxide Production Cheminform. 33: no-no. DOI: 10.1002/chin.200231199 |
0.434 |
|
| 2005 |
Liby K, Hock T, Yore MM, Suh N, Place AE, Risingsong R, Williams CR, Royce DB, Honda T, Honda Y, Gribble GW, Hill-Kapturczak N, Agarwal A, Sporn MB. The synthetic triterpenoids, CDDO and CDDO-imidazolide, are potent inducers of heme oxygenase-1 and Nrf2/ARE signaling. Cancer Research. 65: 4789-98. PMID 15930299 DOI: 10.1158/0008-5472.Can-04-4539 |
0.623 |
|
| 2003 |
Place AE, Suh N, Williams CR, Risingsong R, Honda T, Honda Y, Gribble GW, Leesnitzer LM, Stimmel JB, Willson TM, Rosen E, Sporn MB. The novel synthetic triterpenoid, CDDO-imidazolide, inhibits inflammatory response and tumor growth in vivo. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 9: 2798-806. PMID 12855660 |
0.489 |
|
| 2003 |
Suh N, Roberts AB, Birkey Reffey S, Miyazono K, Itoh S, ten Dijke P, Heiss EH, Place AE, Risingsong R, Williams CR, Honda T, Gribble GW, Sporn MB. Synthetic triterpenoids enhance transforming growth factor beta/Smad signaling. Cancer Research. 63: 1371-6. PMID 12649201 |
0.361 |
|
| 2002 |
Honda T, Honda Y, Favaloro FG, Gribble GW, Suh N, Place AE, Rendi MH, Sporn MB. A novel dicyanotriterpenoid, 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-onitrile, active at picomolar concentrations for inhibition of nitric oxide production. Bioorganic & Medicinal Chemistry Letters. 12: 1027-30. PMID 11909709 DOI: 10.1016/S0960-894X(02)00105-1 |
0.613 |
|
| 1999 |
Pandey P, Avraham S, Kumar S, Nakazawa A, Place A, Ghanem L, Rana A, Kumar V, Majumder PK, Avraham H, Davis RJ, Kharbanda S. Activation of p38 mitogen-activated protein kinase by PYK2/related adhesion focal tyrosine kinase-dependent mechanism. The Journal of Biological Chemistry. 274: 10140-4. PMID 10187797 DOI: 10.1074/Jbc.274.15.10140 |
0.301 |
|
| 1999 |
Pandey P, Avraham S, Place A, Kumar V, Majumder PK, Cheng K, Nakazawa A, Saxena S, Kharbanda S. Bcl-xL blocks activation of related adhesion focal tyrosine kinase/proline-rich tyrosine kinase 2 and stress-activated protein kinase/c-Jun N-terminal protein kinase in the cellular response to methylmethane sulfonate. The Journal of Biological Chemistry. 274: 8618-23. PMID 10085098 DOI: 10.1074/Jbc.274.13.8618 |
0.307 |
|
| 1999 |
Suh N, Wang Y, Honda T, Gribble GW, Dmitrovsky E, Hickey WF, Maue RA, Place AE, Porter DM, Spinella MJ, Williams CR, Wu G, Dannenberg AJ, Flanders KC, Letterio JJ, et al. A novel synthetic oleanane triterpenoid, 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid, with potent differentiating, antiproliferative, and anti-inflammatory activity. Cancer Research. 59: 336-41. PMID 9927043 |
0.556 |
|
| Show low-probability matches. |